Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;42(5):e3306.
doi: 10.1002/hon.3306.

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting

Taku Kikuchi  1 , Nobuhiro Tsukada  1 , Kodai Kunisada  1 , Chiaki Matsumoto  2 , Moe Nomura-Yogo  1 , Yuki Oda  1 , Kota Sato  1 , Tomomi Takei  1 , Mizuki Ogura  1 , Yu Abe  1 , Kenshi Suzuki  1 , Osamu Hosoya  2 , Tadao Ishida  1
Affiliations

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting

Taku Kikuchi et al. Hematol Oncol. 2024 Sep.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Pawlyn C, Cairns D, Kaiser M, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020;34(2):604‐612. https://doi.org/10.1038/s41375‐019‐0595‐5
    1. D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2‐ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406‐3418. https://doi.org/10.1200/JCO.21.02614
    1. Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high‐risk cytogenetic factors: a systematic review and meta‐analysis. JAMA Oncol. 2020;6(11):1759‐1765. https://doi.org/10.1001/jamaoncol.2020.4338
    1. Kanda Y. Investigation of the freely available easy‐to‐use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452‐458. https://doi.org/10.1038/bmt.2012.244
    1. Usmani SZ, Quach H, Mateos MV, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7(14):3739‐3748. https://doi.org/10.1182/bloodadvances.2023010026

MeSH terms

LinkOut - more resources